Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stamm

Showing results (131-140 of 155) with videos related to

Pageof 16
Sort By:
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trialChloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Journal of Viral Hepatitis|October 27, 2022
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 studyKosh Agarwal, Jia Xu, Edward J Gane, et al.
Journal of Viral Hepatitis|March 10, 2016
GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 studyM Rodriguez-Torres, S Glass, J Hill, et al.
Journal of Gastroenterology|September 12, 2018
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trialTetsuo Takehara, Naoya Sakamoto, Shuhei Nishiguchi, et al.
Annals of Internal Medicine|January 1, 1983
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal studyW E Dismukes, A M Stamm, J R Graybill, et al.
Hepatology (Baltimore, Md.)|October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusEric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialAmy E Colson, Anthony M Mills, Moti N Ramgopal, et al.
Journal of Hepatology|August 12, 2018
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patientsChristoph Sarrazin, Curtis L Cooper, Michael P Manns, et al.
Hepatology International|July 22, 2018
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antiviralsNamiki Izumi, Tetsuo Takehara, Kazuaki Chayama, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 27, 2017
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disordersC E Walsh, K Workowski, N A Terrault, et al.
Pageof 16

Showing results (131-140 of 155) with videos related to

Sort By:
Pageof 16
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trialChloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Journal of Viral Hepatitis|October 27, 2022
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 studyKosh Agarwal, Jia Xu, Edward J Gane, et al.
Journal of Viral Hepatitis|March 10, 2016
GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 studyM Rodriguez-Torres, S Glass, J Hill, et al.
Journal of Gastroenterology|September 12, 2018
Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trialTetsuo Takehara, Naoya Sakamoto, Shuhei Nishiguchi, et al.
Annals of Internal Medicine|January 1, 1983
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal studyW E Dismukes, A M Stamm, J R Graybill, et al.
Hepatology (Baltimore, Md.)|October 15, 2014
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virusEric M Yoshida, Mark S Sulkowski, Edward J Gane, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialAmy E Colson, Anthony M Mills, Moti N Ramgopal, et al.
Journal of Hepatology|August 12, 2018
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patientsChristoph Sarrazin, Curtis L Cooper, Michael P Manns, et al.
Hepatology International|July 22, 2018
Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antiviralsNamiki Izumi, Tetsuo Takehara, Kazuaki Chayama, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 27, 2017
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disordersC E Walsh, K Workowski, N A Terrault, et al.
Pageof 16